###begin article-title 0
###xml 48 49 45 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Cysteinyl-leukotrienes in the regulation of beta2-adrenoceptor function: an in vitro model of asthma
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 20 21 17 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 405 407 402 404 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 411 412 408 409 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 447 448 441 442 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
The response to beta2-adrenoceptor agonists is reduced in asthmatic airways. This desensitization may be in part due to inflammatory mediators and may involve cysteinyl-leukotrienes (cysteinyl-LTs). Cysteinyl-LTs are pivotal inflammatory mediators that play important roles in the pathophysiology of asthma, allergic rhinitis, and other inflammatory conditions. We tested the hypothesis that leukotriene D4 (LTD4) and allergen challenge cause beta2-adrenoceptor desensitization through the activation of protein kinase C (PKC).
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 131 133 131 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 261 262 261 262 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 61 66 <span type="species:ncbi:9606">human</span>
###xml 360 365 <span type="species:ncbi:9606">human</span>
The isoproterenol-induced cAMP accumulation was evaluated in human airway smooth muscle cell cultures challenged with exogenous LTD4 or the PKC activator phorbol-12-myristate-13-acetate with or without pretreatments with the PKC inhibitor GF109203X or the CysLT1R antagonist montelukast. The relaxant response to salbutamol was studied in passively sensitized human bronchial rings challenged with allergen in physiological salt solution (PSS) alone, or in the presence of either montelukast or GF109203X.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 26 28 26 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 289 291 289 291 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
In cell cultures, both LTD4 and phorbol-12-myristate-13-acetate caused significant reductions of maximal isoproterenol-induced cAMP accumulation, which were fully prevented by montelukast and GF109203X, respectively. More importantly, GF109203X also prevented the attenuating effect of LTD4 on isoproterenol-induced cAMP accumulation. In bronchial rings, both montelukast and GF109203X prevented the rightward displacement of the concentration-response curves to salbutamol induced by allergen challenge.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 3 5 3 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 17 18 14 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 201 202 195 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 268 269 262 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 51 56 <span type="species:ncbi:9606">human</span>
###xml 166 171 <span type="species:ncbi:9606">human</span>
LTD4 induces beta2-adrenoceptor desensitization in human airway smooth muscle cells, which is mediated through the activation of PKC. Allergen exposure of sensitized human bronchi may also cause a beta2-adrenoceptor desensitization through the involvement of the CysLT1R-PKC pathway.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 12 13 9 10 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 32 33 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 136 137 127 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 262 263 253 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 264 265 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 335 336 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 337 338 325 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 389 390 374 375 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 468 469 450 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 470 471 452 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 488 489 467 468 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 662 663 641 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 664 665 643 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 808 809 787 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 952 954 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 955 957 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1146 1148 1125 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1149 1151 1128 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1237 1239 1216 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1274 1276 1253 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1277 1279 1256 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1300 1302 1279 1281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1303 1305 1282 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1349 1351 1328 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1392 1394 1371 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1453 1455 1432 1434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1456 1458 1435 1437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1533 1534 1509 1510 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1775 1776 1748 1749 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1790 1792 1763 1765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1913 1914 1886 1887 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1929 1930 1902 1903 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 2060 2062 2033 2035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 527 532 <span type="species:ncbi:9606">human</span>
###xml 1498 1503 <span type="species:ncbi:9606">human</span>
Inhaled beta2-adrenoceptor (beta2-AR) agonists represent a first-line treatment of bronchial asthma. However, a reduced response to beta2-AR agonists has been observed in asthmatic subjects and it has been suggested to play a role in airway hyperresponsiveness [1,2]. Although genetic factors may influence responses to beta-agonists [3,4], it is believed that the reduced response of beta2-AR may result from use of beta-agonists leading to receptor desensitization [5,6]. Moreover, beta2-AR desensitization can be induced in human airway smooth muscle cells (HASMC) by exposure to inflammatory mediators that are likely to be present in the asthmatic airways [7,8]. In allergic asthma, several products are released from either resident or circulating inflammatory cells or even from the HASMC themselves [9] upon exposure to allergen. Among these mediators, cysteinyl-leukotrienes (cysteinyl-LTs) are long known to play an important role in asthma [10,11]. Cysteinyl-LTs originate from the oxidative metabolism of arachidonic acid through 5-lipoxygenase in different inflammatory cells and are released upon exposure to sensitizing allergens [12,13]. Cysteinyl-LTs exert a variety of effects with relevance to the etiology of asthma [14], like smooth muscle contraction [15-17] and proliferation [18,19], eosinophil recruitment into the airways [20], increased microvascular permeability [21], enhanced mucus secretion and decreased mucus transport [12,22]. Furthermore, in passively sensitized human bronchi, the response to beta2-AR agonists is reduced after allergen exposure, and this can be prevented by either a cell membrane stabilizer or a leukotriene receptor antagonist, suggesting a role for cysteinyl-LTs released by resident inflammatory cells regulating beta2-AR function [23]. Consistent with this hypothesis is the clinical observation that concurrent administration of salbutamol and the CysLT1receptor (CysLT1R) antagonist montelukast affords greater protection against exercise- and hyperventilation-induced asthma than salbutamol alone [24].
###end p 11
###begin p 12
###xml 71 72 68 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 227 228 221 222 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 417 419 411 413 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 573 574 567 568 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 616 618 610 612 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 760 761 754 755 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 820 821 811 812 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 930 935 <span type="species:ncbi:9606">human</span>
The intracellular mechanisms through which cysteinyl-LTs may cause beta2-AR desensitization in asthmatic airways have not been fully investigated. In the present study, we tested the hypothesis that cysteinyl-LTs may cause beta2-AR desensitization through the activation of protein kinase C (PKC). For this purpose, the isoproterenol-induced cAMP production was first studied in HASMC pre-incubated with exogenous LTD4 or the PKC activator phorbol-12-myristate-13-acetate (PMA). Then, the effects of montelukast and the specific PKC inhibitor GF109203X were compared in LTD4-challenged HASMC. Possible effects of LTD4 on protein kinase A (PKA) or adenylyl-cyclase were assessed by treatments with the PKA inhibitor H89 or forskolin. The hypothesis that the LTD4-PKC pathway may also be involved for allergen-induced beta2-AR desensitization was tested by assessing the effects of montelukast and GF109203X in passively sensitized human bronchial rings challenged with allergen.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Materials
###end title 14
###begin p 15
###xml 243 245 243 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 25 30 <span type="species:ncbi:9606">human</span>
###xml 559 567 <span type="species:ncbi:9606">patients</span>
Smooth muscle cells from human bronchi were purchased from Invitrogen-Cambrex (Walkersville, MD). Cell culture supplies, forskolin, PMA, isobutylmethylxanthine (IBMX) and isoproterenol were purchased from Sigma Chemical Co (St. Louis, MO); LTD4 and cAMP EIA kit from Cayman Chemical Co. (Ann Arbor, MI); montelukast was a gift from Merck & Co. (West Point, PA). GF109203X and H89 were from Calbiochem (La Jolla, CA). DCtrade markProtein assay from Bio-Rad Laboratories (Richmond, CA). Bronchial rings for functional studies were obtained from 6 non-asthmatic patients undergoing thoracotomy for lung cancer.
###end p 15
###begin title 16
HASMC studies
###end title 16
###begin p 17
###xml 190 192 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 220 223 219 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">rd </sup>
###xml 228 231 227 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 262 264 261 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 25 30 <span type="species:ncbi:9606">human</span>
Monolayers of HASMC from human bronchi were grown in Minimum Essential Medium supplemented with 10% FBS, 100-U/ml penicillin, and 100-mug/ml streptomycin, as previously described in detail [25]. Cells were used between 3rd and 8th passage at a 1:3 ratio in 75-cm2 culture flasks. At least two different cell line have been used.
###end p 17
###begin p 18
###xml 184 186 178 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4</sup>
###xml 208 210 202 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-3</sup>
###xml 348 350 341 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
Accumulation of cAMP was measured in cells grown to confluence in 12-well plates and serum-starved for 24 h. Cells were incubated at 37degreesC for 10 min in 1-ml PBS containing 3 x l0-4M ascorbic acid and 10-3M isobutylmethylxanthine. Reactions were stopped by placing the plates on ice, cells were then washed once with cold PBS and 150 mul of l0-1M HC1 were added to each well. After 20-min incubation, cells were scraped and centrifuged 12000 x g for 10 min. Supernatant solutions were first assayed for protein concentration and then for cAMP content using a cAMP EIA-kit following manufacturer's instructions. cAMP concentrations of unknown samples were determined by computer-assisted interpolation from a standard curve.
###end p 18
###begin p 19
###xml 83 85 83 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-9</sup>
###xml 92 94 92 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4</sup>
###xml 173 175 173 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 178 180 178 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 240 242 240 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 308 310 308 310 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
###xml 389 391 389 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 396 398 396 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 407 409 407 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7</sup>
###xml 434 436 434 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 486 488 486 488 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4</sup>
###xml 579 580 579 580 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
Concentration-response curves of cAMP accumulation in response to isoproterenol (10-9M to 10-4M) were obtained in HASMC at control (vehicle treated) or after exposure to LTD4 (10-6M for 30 min), with or without 30-min pre-incubation with 10-6M GF109203X. The increase of cAMP above baseline in response to 10-5M isoproterenol was studied in HASMC at control and after 30-min exposure to 10-6M LTD4 or 5 x l0-7M PMA, with or without 10-6M montelukast, GF109203X, or H89. The effect of 10-4M forskolin was studied by 10-min incubation after 30-min exposure to either vehicle or LTD4.
###end p 19
###begin title 20
Bronchial tissue studies
###end title 20
###begin p 21
###xml 216 217 216 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 225 226 225 226 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 292 294 292 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 303 305 303 305 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 312 313 312 313 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 315 317 315 317 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 327 329 327 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 703 705 701 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7</sup>
###xml 720 722 718 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 749 751 747 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7</sup>
###xml 766 768 764 766 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 1356 1358 1342 1344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 1466 1468 1452 1454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-9</sup>
###xml 1475 1477 1461 1463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4</sup>
###xml 1691 1693 1677 1679 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4</sup>
24 bronchial rings from surgical specimens were passively sensitized against dust mites by an overnight incubation (18 h) at room temperature with serum pooled from three atopic subjects diluted 1:9 in aerated (95% O2, 5 % CO2) PSS of the following composition (mM): NaCl 110.5, KC1 3.4, CaCl2 2.4, MgSO4 0.8, KH2PO4 1.2, NaHCO3 25.7, and dextrose 5.6, as previously described in details [26]. The serum specific concentrations of specific IgE for Dermatophagoides Pteronyssinus and D. Farinae were larger than 13.2 Phadebast RAST units/ml (Pharmacia, Uppsala, Sweden) and the total serum concentration was 180 +/- 33 international units/ml. Nineteen sensitized rings were incubated with montelukast (10-7M, n = 5 and 10-6M, n = 5), or GF109203X (10-7M, n = 2 and 10-6M, n = 1), or PSS (n = 6) for 30 min and then challenged by a 60-min incubation with 200 AU/ml of Dermatophagoides mix at 37degreesC. Challenged rings incubated with PSS alone served as control (n = 6). Rings were then suspended in water-jacketed 25-ml tissue baths containing aerated PSS at 37degreesC using two stirrups connected to a fixed hook at the bottom of the tissue bath and to a force transducer via a silk string, respectively. Rings were gradually stretched until a steady reference length of 1 gr was achieved. PSS was changed every 20 min. All rings were contracted with 10-6M carbachol and, after a steady contraction was achieved, relaxed with salbutamol added cumulatively from 10-9M to 10-4M with half-Log increments. Each concentration-response curve was fitted by sigmoid least-square interpolation between extreme values constrained at 100% (maximal carbachol-induced force) and 0 (minimal force at 10-4M salbutamol).
###end p 21
###begin title 22
Statistical analysis and experimental design
###end title 22
###begin p 23
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
All curves shown were analyzed by Prism-4 software using the four parameters logistic equation and parameters compared using the extra sum of square principle [27]. Parameter errors are expressed as percentage coefficient of variation (%CV) and calculated by simultaneous analysis of at least two different and independent experiments performed in duplicate or triplicate (for HASMC). One-way independent or two-way repeated-measure analysis of variance (ANOVA) were used whenever appropriate with Dunnett or Bonferroni post-hoc tests for multiple comparisons. P values < 0.05 were considered statistically significant. Data are expressed as means +/- S.E.M.
###end p 23
###begin title 24
Results
###end title 24
###begin title 25
Isoproterenol-induced cAMP accumulation in HASMC culture
###end title 25
###begin p 26
Increasing concentrations of isoproterenol caused a concentration-dependent accumulation of cAMP in all experiments.
###end p 26
###begin p 27
###xml 24 26 24 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 32 34 32 34 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 184 187 184 187 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 291 292 289 290 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 316 318 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 464 465 462 463 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
After challenge with LTD4 (Fig. 1A) the maximum cAMP accumulation was significantly (P < 0.05) reduced (33%) from 4109 pmol/mg prot (CV 10%) to 2760 pmoles/mg prot (CV 13%), whereas EC50 was substantially unaffected (from 0.68 muM, CV 59% to 0.69 muM, CV 82%). In montelukast-treated and LTD4-challenged HASMC (Fig. 1B), isoproterenol-induced cAMP accumulation was not significantly different from unchallenged HASMC and significantly greater than in untreated LTD4-challenged HASMC (P < 0.01).
###end p 27
###begin p 28
###xml 23 25 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 0 93 0 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of exogenous LTD<sub>4 </sub>or PMA challenge on isoproterenol-induced cAMP accumulation in HASMC</bold>
###xml 95 98 95 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A-B</italic>
###xml 124 126 124 126 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 130 131 130 131 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 135 137 135 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 181 182 181 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 214 216 214 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 261 262 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 276 277 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 281 283 281 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
###xml 325 326 325 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 382 384 382 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7</sup>
###xml 450 452 450 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 489 491 489 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
Effect of exogenous LTD4 or PMA challenge on isoproterenol-induced cAMP accumulation in HASMC. A-B. Effects of leukotriene D4 (LTD4, 10-6M) challenge and pretreatment with the CysLT1R antagonist montelukast (MK, 10-6M) on cAMP accumulation induced by multiple (A) and single (B, 10-5M) isoproterenol concentrations in HASMC. C. Effect of phorbol-12-myristate-13-acetate (PMA, 5 x l0-7M) challenge and pretreatment with the PKC inhibitor GF109203X (10-6M) on cAMP accumulation induced by 10-5M isoproterenol in HASMC. The results are presented as mean +/- S.E.M. of at least three experiments performed in triplicate. **P < 0.01 (one-way ANOVA).
###end p 28
###begin p 29
###xml 31 33 31 33 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 237 238 232 233 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
After challenge with PMA (Fig. 1C), the maximum isoproterenol-induced cAMP accumulation was significantly (P < 0.01) reduced to 52% +/- 12 SEM of the maximal stimulation, suggesting that PKC plays a pivotal role in the regulation of beta2-AR in HASMC. In GF109203X-treated and PMA-challenged HASMC, isoproterenol-induced cAMP accumulation was not significantly different from unchallenged HASMC and significantly greater than in untreated PMA-challenged HASMC (P < 0.01).
###end p 29
###begin p 30
###xml 46 47 46 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 71 72 71 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 241 242 241 242 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 389 390 389 390 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 403 404 400 401 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
More importantly, in GF109203X-treated and LTD4-challenged HASMC (Fig. 2) the maximal isoproterenol-induced cAMP accumulation was 3417 pmoles/mg prot (CV 5%), significantly (P < 0.01) greater than 2464 pmoles/mg prot (CV 7%) in untreated LTD4-challenged HASMC and insignificantly different from 3632 pmol/mg prot (CV 5%) in unchallenged HASMC, confirming a critical role for PKC in the LTD4-induced beta2-AR desensitization.
###end p 30
###begin p 31
###xml 23 25 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 0 119 0 119 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of exogenous LTD<sub>4 </sub>challenge and pretreatment with GFX109203X on isoproterenol-induced cAMP accumulation in HASMC</bold>
###xml 135 137 135 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 140 142 140 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 190 192 190 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 237 238 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 252 253 252 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 257 259 257 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
Effect of exogenous LTD4 challenge and pretreatment with GFX109203X on isoproterenol-induced cAMP accumulation in HASMC. Effects of LTD4 (10-6M) challenge and pretreatment with GF109203X (10-6M) on cAMP accumulation induced by multiple (A) and single (B, 10-5M) isoproterenol concentrations in HASMC. The results are presented as mean +/- S.E.M. of at least three experiments performed in triplicate. **P < 0.01 (one-way ANOVA).
###end p 31
###begin p 32
###xml 54 56 54 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 147 148 147 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 161 162 158 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 228 230 225 227 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 309 311 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 383 384 380 381 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
Pre-treatment with H89 did not alter the effect of LTD4 challenge on isoproterenol-induced maximal cAMP accumulation (Fig. 3A), suggesting that LTD4-induced beta2-AR desensitization does not involve PKA activation. Moreover, LTD4 challenge did not affect the forskolin-induced maximal cAMP accumulation (Fig. 3B), suggesting that the adenylyl cyclase was not directly affected by LTD4.
###end p 32
###begin p 33
###xml 23 25 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 0 100 0 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of exogenous LTD<sub>4 </sub>challenge on isoproterenol- or forskolin-induced cAMP accumulation in HASMC</bold>
###xml 102 103 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 119 121 119 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 124 126 124 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 186 188 186 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 233 235 233 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
###xml 276 277 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 293 295 293 295 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 298 300 298 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 355 357 355 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4</sup>
Effect of exogenous LTD4 challenge on isoproterenol- or forskolin-induced cAMP accumulation in HASMC. A. Effects of LTD4 (10-6M) challenge and pretreatment with the PKA inhibitor H89 (10-6M) on cAMP accumulation induced by single (10-5M) isoproterenol concentration in HASMC. B. Effects of LTD4 (10-6M) challenge on cAMP accumulation induced by single (10-4M) forskolin concentration in HASMC. The results are presented as mean +/- S.E.M. of at least two experiments performed in triplicate. **P < 0.01, *P < 0.05 (oneway ANOVA).
###end p 33
###begin title 34
###xml 36 41 <span type="species:ncbi:9606">human</span>
Relaxant responses to salbutamol in human bronchial rings
###end title 34
###begin p 35
###xml 267 268 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
The mean weight of the 24 bronchial rings was 91 +/- 5 mg. The mean resting force and the mean normalized-response to carbachol were 0.83 +/- 0.05 g and 14 +/- 2 gr/gr of tissue, without significant differences between sensitized, challenged, and treated rings Table 1.
###end p 35
###begin p 36
###xml 47 52 <span type="species:ncbi:9606">human</span>
Physical and mechanical characteristics of the human bronchial rings used for different experiments.
###end p 36
###begin p 37
Data are mean +/- s.e.m. or individual values.
###end p 37
###begin p 38
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 357 359 357 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 366 368 366 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
###xml 399 401 399 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 408 410 408 410 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7</sup>
###xml 605 607 605 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 614 616 614 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
Salbutamol relaxed bronchial rings significantly (P < 0.01) in a concentration-dependent manner (Fig. 4). The salbutamol concentration-response curve of challenged rings was significantly (P < 0.01) shifted to the right of the dose response curve of sensitized unchallenged rings, with significant differences (P < 0.01) at salbutamol concentrations from 10-6M to 10-5M. Pre-treatment with either 10-6M or 10-7M montelukast displaced significantly (P < 0.01) to the left of the concentration-response curves of challenged rings, with significant differences (P < 0.05) at salbutamol concentrations from 10-6M to 10-5M.
###end p 38
###begin p 39
###xml 0 112 0 112 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of the pretreatment with montelukast on salbutamol-induced relaxation in challenged human bronchial rings</bold>
###xml 265 267 265 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 302 304 302 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4</sup>
###xml 425 427 425 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7</sup>
###xml 474 476 469 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 628 630 621 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 91 96 <span type="species:ncbi:9606">human</span>
###xml 171 176 <span type="species:ncbi:9606">human</span>
Effect of the pretreatment with montelukast on salbutamol-induced relaxation in challenged human bronchial rings. Relaxant responses to salbutamol in carbachol-contracted human bronchial rings. Values of 100 and 0 on y-axis represent maximal force in response to 10-6M carbachol and minimal force at 10-4M salbutamol, respectively. ▲, sensitized control rings (n = 5); ■, challenged-untreated rings (n = 6); o, montelukast 10-7M-treated rings (n = 5); square, montelukast 10-6M-treated rings (n = 5). The results are presented as mean +/- S.E.M. *P < 0.05 (two-way repeated-measure ANOVA followed by Bonferroni post-hoc test) ■ vs. ▲, o, and square.
###end p 39
###begin p 40
###xml 22 25 22 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 164 165 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 174 177 170 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 219 221 215 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 229 231 225 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7</sup>
###xml 385 388 377 380 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 498 500 490 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 521 523 513 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7</sup>
The mean values for IC50 of challenged rings was -5.49 +/- 0.12 Log M significantly (P < 0.05) higher than -6.07 +/- 0.15 Log M of sensitized untreated rings (Fig. 5). The IC50 values of challenged rings treated with 10-6M and 10-7M montelukast were -6.05 +/- 0.03 and 5.96 +/- 0.19, respectively, which were not significantly different from those of sensitized untreated rings. The IC50 values of challenged rings treated with montelukast were lower than those of challenged rings (P < 0.05 for 10-6M and P = 0.07 for 10-7M).
###end p 40
###begin p 41
###xml 0 102 0 102 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Salbutamol concentrations inhibiting 50% of active force in carbachol-contracted human bronchial rings</bold>
###xml 207 209 207 209 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 234 236 234 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 267 269 267 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 294 296 294 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 312 314 312 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7</sup>
###xml 81 86 <span type="species:ncbi:9606">human</span>
Salbutamol concentrations inhibiting 50% of active force in carbachol-contracted human bronchial rings. Effects of montelukast on salbutamol concentrations inhibiting 50% of carbachol-induced contraction (IC50). * P < 0.05 challenged vs. sensitized and montelukast 10-6M, # P = 0.07 challenged vs. montelukast 10-7M (one-way ANOVA followed by Bonferroni post-hoc test). Each symbol represent rings from the same subject.
###end p 41
###begin p 42
###xml 42 44 42 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7</sup>
###xml 51 53 51 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 226 227 226 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
In challenged rings treated with either 10-7M or 10-6M GF109203X, the concentration-response curves to salbutamol were significantly (P < 0.01) shifted to the left of the concentration-response curve of challenged rings (Fig. 6).
###end p 42
###begin p 43
###xml 0 128 0 128 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of the pretreatment with the PKC inhibitor GF109203X on salbutamol-induced relaxation in challenged human bronchial rings</bold>
###xml 286 288 286 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 323 325 323 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4</sup>
###xml 412 414 412 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7</sup>
###xml 454 456 454 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 107 112 <span type="species:ncbi:9606">human</span>
###xml 192 197 <span type="species:ncbi:9606">human</span>
Effect of the pretreatment with the PKC inhibitor GF109203X on salbutamol-induced relaxation in challenged human bronchial rings. Relaxant responses to salbutamol in five carbachol-contracted human bronchial rings. Values of 100 and 0 on y-axis represent maximal force in response to 10-6M carbachol and minimal force at 10-4M salbutamol, respectively. ■, challenged-untreated rings; o, rings pre-treated with 10-7M GF109203X; ▲, ring pre-treated with 10-6M GF109203X.
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 96 98 96 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 233 235 233 235 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 270 271 270 271 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 488 493 <span type="species:ncbi:9606">human</span>
The major findings of the present study can be summarized as follows: 1) In HASMC, exogenous LTD4 caused a reduction of isoproterenol-induced cAMP accumulation similar to that caused by direct activation of PKC, 2) this effect of LTD4 was prevented not only by the CysLT1R antagonist montelukast, but also by direct inhibition of PKC, and 3) both montelukast and direct PKC inhibition prevented the reduction of response to salbutamol caused by allergen challenge of passively sensitized human bronchi.
###end p 45
###begin title 46
Comments on methodology
###end title 46
###begin p 47
###xml 214 216 214 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
###xml 444 445 438 439 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 776 778 770 772 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 880 881 874 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
We first constructed concentration response curves of isoproterenol-induced cAMP accumulation in HASMC utilizing a non-cumulative protocol. A maximum effect was clearly observed at isoproterenol concentration of 10-5M, and this was therefore used for subsequent single-concentration experiments. Isoproterenol was used in cAMP accumulation experiments because, as a full beta-AR agonist, is more suited for the desensitization studies. The beta2-AR selective partial agonist salbutamol was used for bronchial rings studies because it is the reference drug generally used for clinical studies. However, in two separate experiments we found that the effect of salbutamol on cAMP accumulation was much weaker than that of isoproterenol, while the relative reduction caused by LTD4 challenge was similar to that observed using isoproterenol, being even slightly more pronounced (Fig. 7). Therefore, we are confident that the results of our HASMC and bronchial rings studies are comparable.
###end p 47
###begin p 48
###xml 23 25 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 0 83 0 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of exogenous LTD<sub>4 </sub>challenge on salbutamol-induced cAMP accumulation in HASMC</bold>
###xml 98 100 98 100 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 103 105 103 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 152 154 152 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4</sup>
###xml 242 245 242 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
###xml 290 292 290 292 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
Effect of exogenous LTD4 challenge on salbutamol-induced cAMP accumulation in HASMC. Effect of LTD4 (10-6M) challenge on cAMP accumulation induced by 10-4M salbutamol in HASMC. Note the weaker effect of salbutamol compare to isoproterenol (10-5 M) and the similarity with the effects of LTD4 in Fig.s 1-3. The results are presented as mean +/- s.e.m. of two experiments performed in triplicate. *P < 0.01 (one-way ANOVA).
###end p 48
###begin p 49
###xml 36 38 36 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 124 127 124 127 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 495 497 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
Furthermore, the fact that after LTD4 challenge in HASMC only the maximal cAMP accumulation was reduced, whereas only the IC50 of salbutamol-induced relaxation was reduced might be explained by the fact that the relaxing effect of a beta2 agonist is a far more downstream response than a second messenger (i.e. cAMP) production, and certainly involve the activation of other components downstream of the receptor, while the beta2-AR may perform functions other than adenylyl cyclase activation [28], yet equally involved in bronchial relaxation.
###end p 49
###begin p 50
###xml 28 30 28 30 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 31 33 31 33 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 34 36 34 36 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 37 39 37 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 470 472 470 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 834 835 831 832 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 42 47 <span type="species:ncbi:9606">human</span>
As in our previous studies [23,26,29-31], human bronchial rings were passively sensitized by using a pool of sera containing high levels of specific IgEs but low levels of total IgEs. With this method of passive sensitization and allergen challenge, followed by repeated washouts, the force generation capacity of airway smooth muscle was not altered [23], which makes us confident that the reference force of 1 g and the level of pre-contraction induced by carbachol 10-6M were similar in all experimental conditions. Furthermore, the relaxant responses to either theophylline [26] or forskolin [30] remained unaltered in previous studies using the same methodology. Therefore, the use of sensitized unchallenged rings as a control seems justified and any difference in response to salbutamol can be attributed to changes in the beta2-AR pathway.
###end p 50
###begin p 51
###xml 135 137 135 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 142 144 142 144 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 187 189 187 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 215 216 215 216 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 314 315 314 315 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 370 371 367 368 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 463 464 460 461 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 522 524 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
For relaxation studies, bronchial rings were pre-contracted with the non-selective muscarinic agonist carbachol, thus activating both M3 and M2 receptors on smooth muscle cell membrane. M2 receptors are coupled to Gi-protein, which inhibits adenylyl cyclase. Thus, had sensitization or allergen challenge changed Gi-protein expression or activity, the response to a beta2-agonist would have been affected. In this model, however, both expression and activity of Gi-protein were similar in sensitized and challenged rings [29].
###end p 51
###begin p 52
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 233 234 230 231 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 379 380 373 374 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
In bronchial tissue studies, the effects of allergen challenge were presumably due to mediator release from resident inflammatory cells [23]. Thus, it cannot be excluded that the protective effects of GFX and montelukast against beta2-AR dysfunction were in part due to inhibition of mediator release. However, the observation that GFX and montelukast also protected against beta2-AR dysfunction in HASMC does suggest that airway smooth muscle PKC was directly involved
###end p 52
###begin title 53
Comments on results
###end title 53
###begin p 54
###xml 20 21 17 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 98 100 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 117 118 111 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 190 191 181 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 384 386 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 393 394 381 382 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 479 481 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 503 505 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 554 556 542 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 557 559 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 592 593 580 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 594 596 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 637 639 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 763 765 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 842 844 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 845 847 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 935 937 920 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 983 985 968 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 798 804 <span type="species:ncbi:9913">bovine</span>
The response to beta2-AR has been found to be reduced in airways from subjects with fatal asthma [32]. A reduced beta2-AR responsiveness in asthma may be the result of activation of the beta2-AR by specific agonists (homologous desensitization) or activation of other receptors by the inflammatory mediators, which are present in the asthmatic airways (heterologous desensitization) [33]. beta2-AR desensitization induced by agents that increase cAMP levels, such as bradykinin [34] and some cytokines [35] acting through the elevation of prostaglandin E2 [36], is probably regulated by PKA [6,33]. On the contrary, muscarinic agonists [37], phorbol esters, and other inflammatory mediators may attenuate responses to beta-agonists through the activation of PKC [38], as also recently suggested in bovine tracheal smooth muscle preparations [39,40]. However, it appears that these mechanisms of desensitization are cell-type specific [41] and may depend on kinase expression levels [42].
###end p 54
###begin p 55
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 173 174 173 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 211 215 211 215 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q/11</sub>
###xml 255 257 255 257 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 386 388 386 388 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 590 591 587 588 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Among the inflammatory mediators involved in asthma, cysteinyl-LTs seem to play a key role in the bronchoconstrictor response to allergen [15-17] through activation of CysLT1R. Though preferentially coupled to Gq/11-protein, constitutively expressed CysLT1 also activates pertussis toxin (PTX)-sensitive and -insensitive G-proteins [43,44]. In HASMC, we have previously found that CysLT1 stimulation activates PKC [25] and mitogen-activated protein kinases ERK1/2 through mechanisms that involve a PTX-sensitive G-protein [19]. Thus, it is possible that cysteinyl-LTs may contribute to beta2-AR desensitization not only by a PKC-dependent mechanism, but also by modulating the adenylyl cyclase-PKA pathway.
###end p 55
###begin p 56
###xml 140 142 140 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 295 297 295 297 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 375 376 375 376 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 536 537 533 534 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 596 597 593 594 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 221 226 <span type="species:ncbi:9606">human</span>
The results of the present study show that the cAMP accumulation in response to isoproterenol is reduced in HASMC treated with exogenous LTD4 or the PKC activator PMA and the relaxant response to salbutamol is reduced in human bronchi challenged with the sensitizing allergen. The effects of LTD4 in HASMC and allergen challenge in bronchial rings were prevented by the CysLT1R antagonist montelukast and the PKC specific inhibitor GF109203X. Altogether, these findings strongly suggest that in the models used in the present study beta2-AR desensitization was the result of PKC activation by LTD4.
###end p 56
###begin p 57
###xml 23 25 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 131 132 128 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 246 247 243 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 260 261 254 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 437 438 431 432 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 518 519 512 513 <sub xmlns:xlink="http://www.w3.org/1999/xlink">S</sub>
###xml 521 523 515 517 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
###xml 548 549 539 540 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 590 592 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 624 625 615 616 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 662 663 650 651 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 788 789 776 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 843 844 828 829 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
In HASMC, exogenous LTD4 did not alter the cAMP accumulation induced by forskolin, thus excluding that the reduced response of beta2-AR to isoproterenol was due to adenylyl cyclase dysfunction. The PKA inhibitor H89 also failed to prevent the LTD4-induced beta2-AR desensitization in HASMC, thus ruling out the possibility of the involvement of this protein kinase. Indeed, H89 tended to enhance the response to isoproterenol both in LTD4-challenged and -unchallenged HASMC, suggesting the presence of the well known GS/Gi switch phenomenon of beta2-AR coupling due to PKA phosphorylation [45], which was not enhanced by LTD4. This finding suggests that the beta2-AR function is independently modulated by PKA and PKC mechanisms and it is consistent with the observations by Penn et al. [6] who showed that inhibition of PKC did not alter beta2-AR desensitization induced by PKA activation.
###end p 57
###begin p 58
###xml 51 52 48 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 351 353 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 379 381 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 413 414 400 401 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 477 478 464 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 479 481 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 482 484 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 485 487 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 3 8 <span type="species:ncbi:9606">human</span>
In human bronchi, allergen challenge may cause beta2-AR desensitization through different mechanisms involving inflammatory mediators other than LTs, thus possibly involving PKA. However, in previous studies we found that the reduction of relaxant response to salbutamol in allergen-challenged rings was not prevented by inhibition of prostaglandins [23], IL-lbeta, or TNFalpha [30], which are known to cause beta2-AR dysfunction/desensitization through the activation of PKA [6,33,35,36].
###end p 58
###begin title 59
Conclusion
###end title 59
###begin p 60
###xml 97 98 94 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 258 259 255 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 436 437 430 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 511 512 505 506 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 585 586 576 577 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 701 702 692 693 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 724 725 712 713 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 129 134 <span type="species:ncbi:9606">human</span>
In conclusion, taken together these data suggest that cysteinyl-LTs cause desensitization of beta2-AR in both HASMC and isolated human bronchi through an acute mechanism involving PKC but not PKA, and that this desensitization might be prevented by the CysLT1R antagonist montelukast. If cysteinyl-LTs released from resident or circulating inflammatory cells or even from the smooth muscle cell itself are the major responsible for beta2-AR desensitization in asthma, then the concurrent administration of CysLT1R antagonists may represent a useful tool to improve the response to beta2-AR agonists in this disease. Clinical trials are necessary to assess the efficacy of the association between CysLT1R antagonists and beta2-AR agonists in bronchial asthma.
###end p 60
###begin title 61
Competing interests
###end title 61
###begin p 62
GER received a research grant in 2005 from Merck, Sharpe & Dohme for in vitro studies on montelukast.
###end p 62
###begin p 63
MB declare no competing interests.
###end p 63
###begin p 64
SC declare no competing interests.
###end p 64
###begin p 65
LB declare no competing interests.
###end p 65
###begin p 66
SR declare no competing interests.
###end p 66
###begin p 67
MM declare no competing interests
###end p 67
###begin p 68
EC declare no competing interests
###end p 68
###begin p 69
VB received a research grant in 2004 from Merck, Sharpe & Dohme for in vitro studies on montelukast.
###end p 69
###begin title 70
Authors' contributions
###end title 70
###begin p 71
###xml 107 112 <span type="species:ncbi:9606">human</span>
GER conceived and designed the study, coordination and manuscript preparation. MB was involved in isolated human bronchial ring experiments and helped in manuscript preparation.
###end p 71
###begin p 72
SC participated in the design of the experiments, was involved in HASMC culture, performed in vitro cAMP studies and helped in the manuscript preparation.
###end p 72
###begin p 73
###xml 78 83 <span type="species:ncbi:9606">human</span>
LB participated in the design of the experiments and was involved in isolated human bronchial ring experiments.
###end p 73
###begin p 74
SR participated to the in vitro studies.
###end p 74
###begin p 75
###xml 28 33 <span type="species:ncbi:9606">human</span>
MM was involved in isolated human bronchial ring experiments.
###end p 75
###begin p 76
EC participated in the design and coordination of the experiments.
###end p 76
###begin p 77
VB conceived and designed the study and participated to the manuscript preparation.
###end p 77
###begin title 78
Acknowledgements
###end title 78
###begin p 79
This study was supported by grants from Merk Sharp & Dome, Italian Ministry of University and Research (MIUR PRIN 2003 prot. 2003062507 and 2005 prot. 2005069290), and GALEN.
###end p 79
###begin article-title 80
###xml 114 117 <span type="species:ncbi:9615">dog</span>
Impaired beta-adrenergic receptor activation of adenylyl cyclase in airway smooth muscle in the basenji-greyhound dog model of airway hyperresponsiveness
###end article-title 80
###begin article-title 81
Impaired beta-adrenoceptor function, increased leukocyte respiratory burst, and bronchial hyperresponsiveness
###end article-title 81
###begin article-title 82
Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma
###end article-title 82
###begin article-title 83
Hierarchy of polymorphic variation and desensitization permutations relative to beta 1- and beta 2-adrenergic receptor signaling
###end article-title 83
###begin article-title 84
Turning off the signal: desensitization of beta-adrenergic receptor function
###end article-title 84
###begin article-title 85
###xml 79 84 <span type="species:ncbi:9606">human</span>
Mechanisms of acute desensitization of the beta2AR-adenylyl cyclase pathway in human airway smooth muscle
###end article-title 85
###begin article-title 86
Novel beta2-adrenergic receptor signaling pathways
###end article-title 86
###begin article-title 87
Effects of cytokines on contractile and dilator responses of airway smooth muscle
###end article-title 87
###begin article-title 88
Regulation of airway smooth muscle cell immunomodulatory function: role in asthma
###end article-title 88
###begin article-title 89
Leukotrienes and airway responses
###end article-title 89
###begin article-title 90
Leukotrienes as mediators of asthma
###end article-title 90
###begin article-title 91
Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation
###end article-title 91
###begin article-title 92
###xml 130 131 130 131 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 134 136 134 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 141 142 141 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4 and E4
###end article-title 92
###begin article-title 93
Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling
###end article-title 93
###begin article-title 94
###xml 39 44 <span type="species:ncbi:9606">human</span>
Leukotrienes are potent costrictors of human bronchi
###end article-title 94
###begin article-title 95
###xml 47 53 <span type="species:ncbi:9606">humans</span>
Bronchoconstrictor effects of leukotriene C in humans
###end article-title 95
###begin article-title 96
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls
###end article-title 96
###begin article-title 97
###xml 14 16 14 16 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 19 24 <span type="species:ncbi:9606">human</span>
Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction In vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists
###end article-title 97
###begin article-title 98
###xml 24 29 <span type="species:ncbi:9606">human</span>
CysLTl receptor-induced human airway smooth muscle cells proliferation requires ROS generation, EGF receptor transactivation and ERK1/2 phosphorylation
###end article-title 98
###begin article-title 99
The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma
###end article-title 99
###begin article-title 100
Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response
###end article-title 100
###begin article-title 101
Leukotriene generation and clinical implications
###end article-title 101
###begin article-title 102
###xml 85 90 <span type="species:ncbi:9606">human</span>
Anti-inflammatory agents and allergen-induced beta2-receptor dysfunction in isolated human bronchi
###end article-title 102
###begin article-title 103
Bronchoprotective effects of single doses of salmeterol combined with montelukast in thermally induced bronchospasm
###end article-title 103
###begin article-title 104
###xml 62 67 <span type="species:ncbi:9606">human</span>
Leukotriene D4-induced activation of smooth-muscle cells from human bronchi is partly Ca2+-independent
###end article-title 104
###begin article-title 105
###xml 43 48 <span type="species:ncbi:9606">human</span>
Allergen challenge of passively sensitized human bronchi alters M2 and beta2 receptor function
###end article-title 105
###begin article-title 106
G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization
###end article-title 106
###begin article-title 107
###xml 48 53 <span type="species:ncbi:9606">human</span>
G(s) protein dysfunction in allergen-challenged human isolated passively sensitized bronchi
###end article-title 107
###begin article-title 108
###xml 91 96 <span type="species:ncbi:9606">human</span>
Beclomethasone rapidly ablates allergen-induced beta 2-adrenoceptor pathway dysfunction in human isolated bronchi
###end article-title 108
###begin article-title 109
###xml 27 32 <span type="species:ncbi:9606">human</span>
A model of allergen-driven human airway contraction: beta2 pathway dysfunction without cytokine involvement
###end article-title 109
###begin article-title 110
Abnormalities in airway smooth muscle in fatal asthma
###end article-title 110
###begin article-title 111
Desensitization of G-protein-coupled receptors in the cardiovascular system
###end article-title 111
###begin article-title 112
###xml 28 33 <span type="species:ncbi:9606">human</span>
Impaired cAMP production in human airway smooth muscle cells by bradykinin: role of cyclooxygenase products
###end article-title 112
###begin article-title 113
Mechanisms of cytokine effects on G protein-coupled receptor-mediated signaling in airway smooth muscle
###end article-title 113
###begin article-title 114
###xml 75 80 <span type="species:ncbi:9606">human</span>
Prostanoids mediate IL-lbeta-induced beta-adrenergic hyporesponsiveness in human airway smooth muscle cells
###end article-title 114
###begin article-title 115
Modulation of airway smooth muscle beta-adrenoceptor function by a muscarinic agonist
###end article-title 115
###begin article-title 116
Desensitization of the isolated beta 2-adrenergic receptor by beta-adrenergic receptor kinase, cAMP-dependent protein kinase, and protein kinase C occurs via distinct molecular mechanisms
###end article-title 116
###begin article-title 117
###xml 46 52 <span type="species:ncbi:9913">bovine</span>
Potentiation of beta-adrenoceptor function in bovine tracheal smooth muscle by inhibition of protein kinase C
###end article-title 117
###begin article-title 118
###xml 85 91 <span type="species:ncbi:9913">bovine</span>
Protein kinase C potentiates homologous desensitization of the beta2-adrenoceptor in bovine tracheal smooth muscle
###end article-title 118
###begin article-title 119
Oligodeoxynucleotides antisense to mRNA encoding protein kinase A, protein kinase C, and beta-adrenergic receptor kinase reveal distinctive cell-type-specific roles in agonist-induced desensitization
###end article-title 119
###begin article-title 120
Heterogeneity in beta-adrenergic receptor kinase expression in the lung accounts for cell-specific desensitization of the beta2-adrenergic receptor
###end article-title 120
###begin article-title 121
Involvement of prenylated proteins in calcium signaling induced by LTD4 in differentiated U937 cells
###end article-title 121
###begin article-title 122
CysLTl signal transduction in differentiated U937 cells involves the activation of the small GTP-binding protein Ras
###end article-title 122
###begin article-title 123
Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A
###end article-title 123

